Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Immune Response Corp. (NasdaqNM:IMNR)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | SEC | Msgs | Insider | Options | Financials
Recent Events
Aug 14Earnings Announcement
Location
5935 Darwin Court
Carlsbad, CA 92008
Phone: (760) 431-7080
Fax: (760) 431-8636
Email: irc@imnr.com
Employees (last reported count): 129
Financial Links
 ·Top Institutional Holders
 ·Top Mutual Fund Holders
 ·Analyst Upgrade/Downgrade History
 ·Historical Quote Data
 ·Free Annual Report
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Employment
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 12%
·Institutional: 21% (24% of float)
(86 institutions)
·Net Inst. Buying: 1.43M shares (+16.09%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
The Immune Response Corporation is a biopharmaceutical company developing immune-based therapies to induce specific immune responses for the treatment of HIV, autoimmune diseases and cancer. In addition, the Company is developing a targeted, non-viral delivery technology for gene therapy, which is designed to enable the delivery of genes directly to the liver via intravenous injection. The Company's product offerings include REMUNE, which is designed to stimulate an HIV-infected individual's immune system to attack HIV. Products under development include RAVAX, the Company's peptide vaccine therapy being developed is designed to stimulate the immune system of a rheumatoid arthritis patient; ZORCELL, designed to stimulate the immune system of a psoriasis patient to regulate the disease-causing T cells; and NeuroVax, its proprietary immune-based therapy under development for multiple sclerosis.
More from Market Guide: Expanded Business Description

Financial Summary
The Immune Response is a biopharmaceutical company developing immune-based therapies to induce specific T cell response for the treatment of HIV, autoimmune diseases, gene therapy and cancer. For the six months ended 6/30/01, revenues decreased 61% to $2.1 million. Net loss applic to Com. before accounting change totalled $10.5 million, up from $4.1 million. Results reflect decreased milestone payment from Agouron, and decreased investment income.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

James Glavin, 65
Chairman
--  
Dennis Carlo, Ph.D., 57
Pres, CEO, Chief Scientific Officer
$581K
Howard Sampson, 50
CFO, VP-Fin., Sec., Treasurer
308K
John Parker, Ph.D.
VP of Regulatory Affairs and Compliance
--  
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:IMNRAs of 31-Aug-2001
Price and Volume
52-Week Low
on 16-Apr-2001
$1.35 
Recent Price$2.01 
52-Week High
on 1-Sep-2000
$9.625
Beta1.25 
Daily Volume (3-month avg)914.6K
Daily Volume (10-day avg)182.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change-78.3%
52-Week Change
relative to S&P500
-70.8%
Share-Related Items
Market Capitalization$70.6M
Shares Outstanding35.1M
Float30.9M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$0.47 
Earnings (ttm)-$0.56 
Earnings (mrq)-$0.16 
Sales (ttm)$0.19 
Cash (mrq)$0.36 
Valuation Ratios
Price/Book (mrq)4.32 
Price/EarningsN/A 
Price/Sales (ttm)10.69 
Income Statements
Sales (ttm)$5.83M
EBITDA (ttm)-$18.9M
Income available to common (ttm)-$17.1M
Profitability
Profit MarginN/A 
Operating MarginN/A 
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-39.73%
Return on Equity (ttm)-79.15%
Financial Strength
Current Ratio (mrq)1.66 
Debt/Equity (mrq)0.13 
Total Cash (mrq)$12.6M
Short Interest
As of 8-Aug-2001
Shares Short2.72M
Percent of Float8.8%
Shares Short
(Prior Month)
2.84M
Short Ratio14.11 
Daily Volume193.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Event data provided by CCBN. Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.